Evidence map›Paper›PMID 24970562›Full record

ArticleBMC medical genetics2014

Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39.

Rossella Melchiotti, Kia Joo Puan, Anand Kumar Andiappan, Tuang Yeow Poh, Mireille Starke, Li Zhuang, Kerstin Petsch, Tuck Siong Lai, Fook Tim Chew, Anis Larbi and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. CD39 Regulation and Functions in T Cells.International journal of molecular sciences · 2021
    Review
  9. Review
  10. Article
  11. ER-phagy and human diseases.Cell death and differentiation · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Rossella Melchiotti
Kia Joo Puan
Anand Kumar Andiappan
Tuang Yeow Poh
Mireille Starke
Li Zhuang
Kerstin Petsch
Tuck Siong Lai
Fook Tim Chew
Anis Larbi
De Yun WangSIgN (Singapore Immunology Network), A*STAR (Agency for Science, Technology and Research), Singapore 138648, Singapore. entwdy@nus.edu.sg.
Michael Poidinger
Olaf Rotzschke
Singapore Immunology Network · SGAgency for Science, Technology and Research · SGNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtracellular ATP is a pro-inflammatory molecule released by damaged cells. Regulatory T cells (Treg) can suppress inflammation by hydrolysing this molecule via ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), also termed as CD39. Multiple studies have reported differences in CD39+ Treg percentages in diseases such as multiple sclerosis, Hepatitis B and HIV-1. In addition, CD39 polymorphisms have been implicated in immune-phenotypes such as susceptibility to inflammatory bowel disease and AIDS progression. However none of the studies published so far has linked disease-associated variants with differences in CD39 Treg surface expression. This study aims at identifying variants affecting CD39 expression on Treg and at evaluating their association with allergic rhinitis, a disease characterized by a strong Treg involvement.

methodsCohorts consisting of individuals of different ethnicities were employed to identify any association of CD39 variants to surface expression. Significant variant(s) were tested for disease association in a published GWAS cohort by one-locus and two-locus genetic analyses based on logistic models. Further functional characterization was performed using existing microarray data and quantitative RT-PCR on sorted cells.

resultsOur study shows that rs7071836, a promoter SNP in the CD39 gene region, affects the cell surface expression on Treg cells but not on other CD39+ leukocyte subsets. Epistasis analysis revealed that, in conjunction with a SNP upstream of the FAM134B gene (rs257174), it increased the risk of allergic rhinitis (P = 1.98 × 10-6). As a promoter SNP, rs257174 controlled the expression of the gene in monocytes but, notably, not in Treg cells. Whole blood transcriptome data of three large cohorts indicated an inverse relation in the expression of the two proteins. While this observation was in line with the epistasis data, it also implied that a functional link must exist. Exposure of monocytes to extracellular ATP resulted in an up-regulation of FAM134B gene expression, suggesting that extracellular ATP released from damaged cells represents the connection for the biological interaction of CD39 on Treg cells with FAM134B on monocytes.

conclusionsThe interplay between promoter SNPs of CD39 and FAM134B results in an intercellular epistasis which influences the risk of a complex inflammatory disease.

Indexed as

Epistasis, GeneticAntigens, CDApyraseCase-Control StudiesGenetic VariationHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsMonocytesNeoplasm ProteinsPolymorphism, Single NucleotidePromoter Regions, GeneticReproducibility of ResultsRhinitis, AllergicRhinitis, Allergic, PerennialT-Lymphocytes, RegulatoryAntigens, CDApyraseCD39 antigenIntracellular Signaling Peptides and ProteinsMembrane ProteinsNeoplasm ProteinsRETREG1 protein, human

Identifiers

PMID24970562
PMCPMC4094447
OpenAlexW2058283959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.